1. Carbosilane Glycodendrimers for Anticancer Drug Delivery: Synthetic Route, Characterization, and Biological Effect of Glycodendrimer-Doxorubicin Complexes
- Author
-
Monika Müllerová, Dina Maciel, Nádia Nunes, Dominika Wrobel, Marcel Stofik, Lucie Červenková Št́astná, Alena Krupková, Petra Cuřínová, Kateřina Nováková, Matěj Božík, Marek Malý, Jan Malý, João Rodrigues, and Tomáš Strašák
- Subjects
Ovarian Neoplasms ,Drug Carriers ,Polymers and Plastics ,Bioengineering ,Antineoplastic Agents ,Silanes ,Polyethylene Glycols ,Biomaterials ,Drug Liberation ,Drug Delivery Systems ,Doxorubicin ,Cell Line, Tumor ,Materials Chemistry ,Humans ,Female - Abstract
The complexity of drug delivery mechanisms calls for the development of new transport system designs. Here, we report a robust synthetic procedure toward stable glycodendrimer (glyco-DDM) series bearing glucose, galactose, and oligo(ethylene glycol)-modified galactose peripheral units. In vitro cytotoxicity assays showed exceptional biocompatibility of the glyco-DDMs. To demonstrate applicability in drug delivery, the anticancer agent doxorubicin (DOX) was encapsulated in the glyco-DDM structure. The anticancer activity of the resulting glyco-DDM/DOX complexes was evaluated on the noncancerous (BJ) and cancerous (MCF-7 and A2780) cell lines, revealing their promising generation- and concentration-dependent effect. The glyco-DDM/DOX complexes show gradual and pH-dependent DOX release profiles. Fluorescence spectra elucidated the encapsulation process. Confocal fluorescence microscopy demonstrated preferential cancer cell internalization of the glyco-DDM/DOX complexes. The conclusions were supported by computer modeling. Overall, our results are consistent with the assumption that novel glyco-DDMs and their drug complexes are very promising in drug delivery and related applications.
- Published
- 2021